HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $425
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) and increased the price target from $405 to $425.

March 15, 2024 | 10:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed its Buy rating on Madrigal Pharmaceuticals and raised its price target from $405 to $425.
The reaffirmation of the Buy rating and the increase in price target by HC Wainwright & Co. are strong positive signals for Madrigal Pharmaceuticals. This suggests confidence in the company's future performance and potential for stock price appreciation. The specific increase in the price target is likely to influence investor sentiment positively in the short term, potentially leading to an increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100